{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Quantum Biopharma Ltd."},"Symbol":{"label":"Symbol","value":"QNTM"},"Address":{"label":"Address","value":"55 UNIVERSITY AVENUE,SUITE 1003 SUITE 1003, TORONTO, Ontario, M5J 2H7, Canada"},"Phone":{"label":"Phone","value":"+1 647 864-7969"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ('Lucid-MS'). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma has also licensed unbuzzd(TM), a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. ('Celly Nu')."},"CompanyUrl":{"label":"Company Url","value":"www.quantumbiopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrzej Chruscinski","title":"Vice President-Clinical & Scientific Affairs"},{"name":"Zeeshan Saeed","title":"Executive Co-Chairman, President & CEO"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}